These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29513767)

  • 1. Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
    Keller S; Aigner A; Zenouzi R; Kim AC; Meijer A; Weidemann SA; Krech T; Lohse AW; Adam G; Schramm C; Yamamura J
    PLoS One; 2018; 13(3):e0193929. PubMed ID: 29513767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis.
    Keller S; Sedlacik J; Schuler T; Buchert R; Avanesov M; Zenouzi R; Lohse AW; Kooijman H; Fiehler J; Schramm C; Yamamura J
    Eur Radiol; 2019 Feb; 29(2):818-828. PubMed ID: 30014204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians?
    Keller S; Venkatesh SK; Avanesov M; Weinrich JM; Zenouzi R; Schramm C; Adam G; Yamamura J
    Clin Radiol; 2018 Jul; 73(7):677.e1-677.e6. PubMed ID: 29576223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
    Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
    Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease.
    Bader TR; Beavers KL; Semelka RC
    Radiology; 2003 Mar; 226(3):675-85. PubMed ID: 12616016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis.
    Petrovic BD; Nikolaidis P; Hammond NA; Martin JA; Petrovic PV; Desai PM; Miller FH
    Dig Dis Sci; 2007 Dec; 52(12):3499-506. PubMed ID: 17410447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging.
    Verloh N; Probst U; Utpatel K; Zeman F; Brennfleck F; Werner JM; Fellner C; Stroszczynski C; Evert M; Wiggermann P; Haimerl M
    PLoS One; 2019; 14(5):e0215752. PubMed ID: 31083680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver MRI and histological correlates in chronic liver disease on multiphase gadolinium-enhanced 3D gradient echo imaging.
    Martin DR; Lauenstein T; Kalb B; Lurie C; Kitajima H; Sharma P; Salman K; Moreira R; Farris AB; Spivey J; Martinez E; Hanish S; Adsay V
    J Magn Reson Imaging; 2012 Aug; 36(2):422-9. PubMed ID: 22566123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of magnetic resonance elastography in primary sclerosing cholangitis.
    Eaton JE; Dzyubak B; Venkatesh SK; Smyrk TC; Gores GJ; Ehman RL; LaRusso NF; Gossard AA; Lazaridis KN
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1184-90. PubMed ID: 26691631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis.
    Mesropyan N; Kupczyk P; Kukuk GM; Dold L; Weismueller T; Endler C; Isaak A; Faron A; Sprinkart AM; Pieper CC; Kuetting D; Strassburg CP; Attenberger UI; Luetkens JA
    BMC Med Imaging; 2021 Apr; 21(1):65. PubMed ID: 33827475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
    Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
    Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI.
    Jang YJ; Cho SH; Bae JH; Kim GC; Ryeom H; Kim HJ; Shin KM; Lee HJ
    Ann Hepatol; 2013; 12(6):926-34. PubMed ID: 24114823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Kawada H; Moriyama N; Bae KT
    J Magn Reson Imaging; 2012 Nov; 36(5):1148-53. PubMed ID: 22848019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis.
    Schulze J; Lenzen H; Hinrichs JB; Ringe B; Manns MP; Wacker F; Ringe KI
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):192-199.e3. PubMed ID: 29775791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting liver fibrosis with Gd-EOB-DTPA-enhanced MRI: A confirmatory study.
    Verloh N; Utpatel K; Haimerl M; Zeman F; Beyer L; Fellner C; Brennfleck F; Dahlke MH; Stroszczynski C; Evert M; Wiggermann P
    Sci Rep; 2018 Apr; 8(1):6207. PubMed ID: 29670136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease.
    Hayashi T; Saitoh S; Fukuzawa K; Tsuji Y; Takahashi J; Kawamura Y; Akuta N; Kobayashi M; Ikeda K; Fujii T; Miyati T; Kumada H
    Gut Liver; 2017 Sep; 11(5):674-683. PubMed ID: 28651300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis.
    de Vries EM; Verheij J; Hubscher SG; Leeflang MM; Boonstra K; Beuers U; Ponsioen CY
    J Hepatol; 2015 Nov; 63(5):1212-9. PubMed ID: 26095184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.
    Ding Y; Rao S; Yang L; Chen C; Zeng M
    Radiol Med; 2016 Nov; 121(11):821-827. PubMed ID: 27449761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic Acid.
    Chen BB; Hsu CY; Yu CW; Wei SY; Kao JH; Lee HS; Shih TT
    Invest Radiol; 2012 Nov; 47(11):649-55. PubMed ID: 23011189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials.
    Huh J; Ham SJ; Cho YC; Park B; Kim B; Woo CW; Choi Y; Woo DC; Kim KW
    BMC Med Imaging; 2019 Nov; 19(1):89. PubMed ID: 31729971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.